Literature DB >> 15266253

Cognitive effects of olanzapine treatment in schizophrenia.

Susan R McGurk1, M A Lee, K Jayathilake, Herbert Y Meltzer.   

Abstract

Improvement in some but not all domains of cognition during treatment with the atypical antipsychotic drugs clozapine, quetiapine, olanzapine, and risperidone has been reported in some but not all studies. It has been recently suggested that these reports are an artifact, related to lessening of the impairment due to typical neuroleptic drugs and anticholinergic agents. The purpose of this study was to further test the hypothesis that olanzapine, an atypical antipsychotic drug reported to have anticholinergic properties, improves cognition in patients with schizophrenia, including domains of cognition related closely to work and social function (ie, verbal learning and memory) and that this improvement is independent of improvement in psychopathology. Thirty-four patients with schizophrenia who were partial responders to typical antipsychotic drug treatment were evaluated with a comprehensive neurocognitive battery, including measures of executive functioning; verbal and visual learning and memory; working memory; immediate, selective, and sustained attention; perceptual/motor processing; and motor skills prior to and following treatment with olanzapine for 6 weeks. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology in patients treated with typical antipsychotic drugs. Subjects were switched to olanzapine (average dose 13.4 mg, range 5-20 mg) and reassessed following 6 weeks and 6 months of treatment. Significant improvement was noted in 9 of 19 cognitive tests, including measures of selective attention, verbal learning and memory, and verbal fluency. No cognitive test was worsened by olanzapine treatment. Improvements in the BPRS Total and Positive Symptom Subscale scores were noted. Improvements in verbal learning and memory, sustained attention, and psychomotor tracking were independent of improvement in psychopathology. These data suggest that olanzapine improved some but not all cognitive deficits in schizophrenia, including verbal memory, a cognitive domain impaired by anticholinergic drugs. The basis for the improvement in cognitive scores, which should lead to improvement in role functioning if real, is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266253      PMCID: PMC1395781     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  64 in total

Review 1.  Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies.

Authors:  A S Bellack; J M Gold; R W Buchanan
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

2.  Short-term retention of individual verbal items.

Authors:  L R PETERSON; M J PETERSON
Journal:  J Exp Psychol       Date:  1959-09

3.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

4.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

5.  Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia.

Authors:  R S Goldman; B N Axelrod; R Tandon; S C Ribeiro; K Craig; S Berent
Journal:  Psychopathology       Date:  1993       Impact factor: 1.944

6.  Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.

Authors:  Junji Ichikawa; Zhu Li; Jin Dai; Herbert Y Meltzer
Journal:  Brain Res       Date:  2002-11-29       Impact factor: 3.252

7.  Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.

Authors:  Susan R McGurk; Michael F Green; William C Wirshing; Donna Ames Wirshing; Steven R Marder; Jim Mintz; Robert Kern
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

Review 8.  Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients.

Authors:  G Cassens; A K Inglis; P S Appelbaum; T G Gutheil
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

9.  The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results.

Authors:  D L Braff; R Heaton; J Kuck; M Cullum; J Moranville; I Grant; S Zisook
Journal:  Arch Gen Psychiatry       Date:  1991-10

10.  The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

Authors:  T E Goldberg; R D Greenberg; S J Griffin; J M Gold; J E Kleinman; D Pickar; S C Schulz; D R Weinberger
Journal:  Br J Psychiatry       Date:  1993-01       Impact factor: 9.319

View more
  12 in total

1.  Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.

Authors:  Toshikazu Ikuta; Delbert G Robinson; Juan A Gallego; Bart D Peters; Patricia Gruner; John Kane; Majnu John; Serge Sevy; Anil K Malhotra; Philip R Szeszko
Journal:  Psychiatry Res       Date:  2013-10-10       Impact factor: 3.222

2.  The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.

Authors:  Donnie Eddins; Terence G Hamill; Vanita Puri; Christopher E Cannon; Jeffrey A Vivian; Sandra M Sanabria-Bohórquez; Jacquelynn J Cook; John A Morrow; Fiona Thomson; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2013-09-20       Impact factor: 4.530

3.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

4.  A review of executive function deficits and pharmacological management in children and adolescents.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2012-08

Review 5.  Potential of Oxytocin in the Treatment of Schizophrenia.

Authors:  Paul D Shilling; David Feifel
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

6.  Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.

Authors:  Hong Liu-Seifert; Haya Ascher-Svanum; Olawale Osuntokun; Kai Yu Jen; Juan Carlos Gomez
Journal:  BMC Psychiatry       Date:  2011-05-17       Impact factor: 3.630

7.  Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jaume Aguado; Zhanglin Cui
Journal:  Qual Life Res       Date:  2012-12-14       Impact factor: 4.147

8.  Executive Dysfunction among Children with Antipsychotic Treated Schizophrenia.

Authors:  Tjhin Wiguna; Anthony Paul Sison Guerrero; Shuji Honjo; Irawati Ismail; Noorhana Setyowati Wr; Fransiska Kaligis
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

9.  The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks in vitro.

Authors:  Egor Dzyubenko; Georg Juckel; Andreas Faissner
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

10.  Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects.

Authors:  Magdalena Białoń; Marcelina Żarnowska; Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik
Journal:  Psychopharmacology (Berl)       Date:  2020-02-20       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.